TIDMMPH

RNS Number : 1632N

Mereo BioPharma Group plc

20 September 2019

Mereo BioPharma Group plc

("Mereo" or the "Company")

Notification of Director Dealing

London, September 20, 2019 - Mereo BioPharma Group plc (AIM: MPH, NASDAQ: MREO), a clinical stage UK based biopharmaceutical company focused on rare diseases, received notification that on September 19, 2019, Denise Scots-Knight, Chief Executive Officer of Mereo, purchased 13,500 Ordinary Shares at a price of GBP0.59 per share.

The below announcement and notification is made in accordance with the EU Market Abuse Regulation. The form required under the EU Market Abuse Regulation follows.

 
 1    Details of the person discharging managerial responsibilities 
 a)   Name                      Denise Scots-Knight 
     ------------------------  ------------------------------------------ 
 2    Reason for the notification 
     -------------------------------------------------------------------- 
 a)   Position/status           Chief Executive Officer 
     ------------------------  ------------------------------------------ 
 b)   Initial notification/     Initial notification 
       Amendment 
     ------------------------  ------------------------------------------ 
 3    Details of the issuer, emission allowance market participant, 
       auction platform, auctioneer or auction monitor 
     -------------------------------------------------------------------- 
 a)   Name                      Mereo BioPharma Group plc 
     ------------------------  ------------------------------------------ 
 b)   LEI                       213800U8JQHIJOS5AS09 
     ------------------------  ------------------------------------------ 
 4    Details of the transaction(s): section to be repeated for 
       (i) each type of instrument; (ii) each type of transaction; 
       (iii) each date; and (iv) each place where transactions have 
       been conducted 
     -------------------------------------------------------------------- 
 a)   Description of            MEREO BIOPHARMA GROUP PLC ORDINARY SHARES 
       the financial 
       instrument, type 
       of instrument 
       and identification 
       code 
     ------------------------  ------------------------------------------ 
 b)   Nature of the             PURCHASE 
       transaction 
     ------------------------  ------------------------------------------ 
 c)   Price(s) and                Price(s)    Volume(s) 
       volume(s)                   GBP0.59     13,500 
                                              ---------- 
     ------------------------  ------------------------------------------ 
 d)   Aggregated information:   Aggregated volume: 13,500 
       volume, Price             Aggregated price: GBP0.59 
     ------------------------  ------------------------------------------ 
 e)   Date of the transaction   2019-09-19 
     ------------------------  ------------------------------------------ 
 f)   Place of the              AIMX 
       transaction 
     ------------------------  ------------------------------------------

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

DSHLMMJTMBBTBLL

(END) Dow Jones Newswires

September 20, 2019 09:22 ET (13:22 GMT)

Mereo Biopharma (LSE:MPH)
Gráfico Histórico do Ativo
De Jan 2025 até Fev 2025 Click aqui para mais gráficos Mereo Biopharma.
Mereo Biopharma (LSE:MPH)
Gráfico Histórico do Ativo
De Fev 2024 até Fev 2025 Click aqui para mais gráficos Mereo Biopharma.